Welcome to PetLife Pharmaceuticals!

We know how important your animal is to you

We are passionate The World's First Blue Scorpion Reservation

Pets Age. We Age.





"Disrupting the Multi-Billion Dollar Pet Cancer Market. Invest in your future, Invest in your pet’s."

How many companion animals are diagnosed each year with cancer? Every day 10,000 dogs and 6,000 cats are diagnosed with cancer.
​There are 65 million dogs and 32 million cats in the United States. Of these, roughly 6 million new cancer diagnoses are made in dogs and a similar number made in cats each year

PRESS NEWS:




World Renowned Veterinary Nutritionist Dr. R. Geoffrey Broderick Continues Groundbreaking Efforts to Help Animals by Joining PetLife Pharmaceuticals, Inc. as the Chairman of Product Development and Advisory Board

Hancock, MD, Feb. 09, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, augments the advisory board and prepares for new and expanded product lines with the appointment of Dr. R. Geoffrey Broderick as Chairman of Product Development. Dr. Broderick, one of the world’s most famous veterinarians, comes to PetLife with an intricate knowledge of the pet industry.

View Yahoo Finance
View Press Release

OUR MISSION


PetLife Pharmaceuticals, Inc., (OTC:PTLF) is launching a new generation of all natural veterinary cancer medications and nutraceuticals, based on the venom of the Caribbean Blue Scorpion. PetLife's new product line, "Vitalzul for Pets™". The company’s mission is to bring several non-invasive treatments to market with the goal of improving the quality of life in our companion animals. The anticipated registration of an FDA approved drug, “Vitalzul™”, for the treatment of cancer in animals, as well as the introduction of nutraceuticals, food, and pet treats, are all in the works today.

PetLife Pharmaceuticals reports the First of Three Preclinical Studies in their pre-INAD Process for Vitalzul. Blue Scorpion Venom Toxicity Study Results Show No Adverse Reactions across Multiple Dosing Levels. View Press Release




FUTURE FEATURED PRODUCTS


VITALZUL™ – The pharmaceutical grade product will have multiple mechanisms for delivery including; Oral, Injectable, IV and an Enema Solution.

VITALZUL Daily™ – Oral daily supplement given as a preventive measure to build immunity and lower your pet’s odds of getting cancer

VITALZUL Pet Foods™ – a natural pet food embedded with VITALZUL’s life preserving formula to build immunity and lower your pet’s odds of getting cancer

REGISTER FOR PETLIFE EVENTS


Click here to load this Caspio Cloud Database







WHAT IS VITALZUL™?


• Vitalzul’s™ patented formula is an innovative potentiated bio-active peptide extracted from the Caribbean Blue Scorpion (Rhopalurus Junceus) used to treat dogs and cats diagnosed with cancer

THE PROBLEM


• 1/4 of dogs and 1/5 of cats will develop cancer in their lifetime!
• Cancer is the #1 disease related cause of death in dogs in the US
• Cancer accounts for almost 50% of deaths in pets older than 10
• Conventional treatment can cost SEVERAL thousands of dollars, forcing pet owners to watch their pet slowly deteriorate

HOW ARE WE DIFFERENT?


• UNLIKE conventional treatment, Vitalzul™ has the proven ability to reduce tumor size- with NO signs of toxicity or complications observed during clinical use
• Binds preferentially to abnormal cells
• Reduces the painful side-effects of chemotherapy and radiation
• Increased appetite and energy levels




New frontier in pet oncological treatment; based on blue scorpion venom, which has been used for years to treat humans with cancer in many countries.


This product has not been approved by the FDA or the Center for Veterinary Medicine for the treatment, cure or prevention of cancer or any other disease in animals. Currently, Vitalzul is a nutraceutical product and falls under the category of a Dietary Supplement. All testimonies in this video are factual but can only be considered anecdotal . These testimonies may not be representative of a typical response to the use of the product in any individual animal.
PetLife Pharmaceuticals is introducing a new break through pet cancer drug that is anticipated to begin FDA trials in the upcoming months. The drug is an all natural compound. The FDA trials are estimated to take approximately 18-24 months. PetLife Pharmaceuticals, Inc. is a publicly traded company. The stock symbol is PTLF on the OTCQB market. PetLife is a new biotech company developing products to address disease in our companion pets and livestock. Request Information

This product has not been approved by the FDA or the Center for Veterinary Medicine for the treatment, cure or prevention of cancer or any other disease in animals. Currently, Vitalzul is a nutraceutical product and falls under the category of a Dietary Supplement. All testimonies in this video are factual but can only be considered anecdotal. These testimonies may not be representative of a typical response to the use of the product in any individual animal. The securities may only be sold to accredited investors which for natural persons are investors who meet a minimum certain annual income or network thresholds; 105. The securities are being offered on a reliance on an exemption from the registration requirements of the securities act and are not required to comply with specific disclosure requirements that apply to registration under the securities act. The commission has not has passed upon the merits of or given the approval to the securities the terms of the offering, or the accuracy or completeness of any offering materials; The securities are subject to legal restrictions and transfer and resale and investors should not assume they will be able to resell their securities; and investing in securities involve risk and investors should be able to bear the loss of their investment.

faqs

Learn more about our company by reading through our FAQs

our team

Meet our team and have the opportunity to ask them questions

pet life

A New Generation of Veterinary Nutraceuticals and Medicines

Vet Endorsements

October 10 2014

Miami based Veterinarian, Dr. Raul Jimenez describes his feelings about Vitalzul for Pets™

October 26 2014

Santo Domingo based Veterinarian, Dr. Patricia Mendez reports her observational study using Vitalzul for Pets™

November 05 2014

Dr. Joel Beth Mitchell-Navratik supports her ongoing clinical study using Vitalzul for Pets™ with 7 week, time-lapsed X-Rays.

Related News

November 2014

California based Company's Cancer Fighting Serum made from Peptides found in Scorpion Venom - Nightline News

July 23 2014

Doctor explains how Scorpion Venom could Help Fight Cancer - FOX News Insider

August 04 2014

Bee, Scorpion & Snake Venom may hold Cancer Cure - CNN

Press Release

February 20, 2017

PetLife Pharmaceutical Taps National Public Relations Firm to Help Bring to Market Cancer Treatment Originally Developed by Cuba- HANCOCK, Md.--(BUSINESS WIRE)--PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it has retained Gregory FCA Communications, Inc., one of the nation’s largest public relations agencies, to help bring to market a breakthrough cancer treatment for pets produced from the venom of the blue scorpion.
VIEW PRESS RELEASE

February 10, 2017

World Renowned Veterinary Nutritionist Dr. R. Geoffrey Broderick Continues Groundbreaking Efforts to Help Animals by Joining PetLife Pharmaceuticals, Inc. as the Chairman of Product Development and Advisory Board - Hancock, MD, Feb. 09, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, augments the advisory board and prepares for new and expanded product lines with the appointment of Dr. R. Geoffrey Broderick as Chairman of Product Development. Dr. Broderick, one of the world’s most famous veterinarians, comes to PetLife with an intricate knowledge of the pet industry.
VIEW PRESS RELEASE

February 3, 2017

PetLife Pharmaceuticals Announces Son of World Famous Veterinarian & Pet Industry Innovator, Geoffrey Broderick, to Join the Company as the New President. Hancock, MD, Feb. 03, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to announce the addition of Geoffrey Broderick, who comes to PetLife with extensive experience in the pet industry, as the new company President.
VIEW PRESS RELEASE

January 10, 2017

PetLife Pharmaceuticals reports the First of Three Preclinical Studies in their pre-INAD Process for Vitalzul. Blue Scorpion Venom Toxicity Study Results Show No Adverse Reactions across Multiple Dosing Levels.
VIEW PRESS RELEASE

December 7, 2016

PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line
VIEW PRESS RELEASE

December 6, 2016

PetLife Pharmaceuticals’ CEO Dr. Salvagno Provides White Paper on “Venenotherapy” While Preparing for FDA Submission
VIEW PRESS RELEASE

December 1, 2016

PetLife Pharmaceuticals Updates Shareholders on the Company Progress with Vitalzul™ Studies and Additional Product Offerings
VIEW PRESS RELEASE

November 15, 2016

PetLife Pharmaceuticals Notes Recent Cuban Research Providing Profound Evidence of Caribbean Blue Scorpion Venom's Ability to Eradicate Cancer Cells as Continued Support for PetLife's pre- INAD Studies of Vitalzul™
VIEW PRESS RELEASE

October 27, 2016

PetLife Pharmaceuticals and Lumleian, LLC Announce Partnership to Advance Development and Commercialization of Promising Veterinary Health Pipeline
VIEW PRESS RELEASE

October 24, 2016

PetLife Pharmaceuticals Announces the Addition of a Seasoned Marketing Specialist and Investor, Mrs. Vyvyan Campbell, to the Board of Directors
VIEW PRESS RELEASE

October 19, 2016

PetLife Pharmaceuticals Announces the Addition of Dr. Simon Wood PhD as the Company’s new Scientific Officer with plans to expand its Current Portfolio of Veterinarian Drugs and Nutraceuticals
VIEW PRESS RELEASE

VIEW ALL PRESS RELEASES

Press Release Archives
VIEW ALL PRESS RELEASE INFORMATION

Contact Information

Information

Contact for additional information:

info@petlifepharma.com or call us

(844)473-8543

(844)4PETLIFE

Headquarters

PetLife Pharmaceuticals Inc.
38 West Main Street
Hancock, MD 21750



Satellite Offices:
Los Angeles, California
San Diego, California

Click here to load this Caspio Cloud Database